Nab-Paclitaxel (Abraxane)
Other Medications · Approved since 2005
Description
Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, a taxane chemotherapy agent used in metastatic colorectal cancer, typically in later-line treatment settings or clinical trial combinations. This formulation allows for higher drug concentrations and improved tumor penetration compared to conventional paclitaxel while avoiding the hypersensitivity reactions associated with solvent-based formulations. In CRC, it is most commonly employed when patients have progressed on standard therapies including fluoropyrimidines, oxaliplatin, and irinotecan-based regimens.
Mechanism of Action
Nab-paclitaxel binds to beta-tubulin subunits within cancer cells, stabilizing microtubules and preventing their normal disassembly during cell division. This disruption of microtubule dynamics arrests cells in the G2/M phase of the cell cycle, ultimately triggering apoptotic cell death. The albumin-bound nanoparticle formulation enhances drug delivery to tumors through increased vascular permeability and albumin receptor-mediated uptake.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Abraxane |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 2005 |
| Clinical Trials | 17 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.